Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating the efficacy and safety of subcutaneous JS005 in adults with moderate to severe chronic plaque psoriasis has comple…
-
FDA approval · 2025-12-12FDA Approved: ILUMYA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ILUMYA (tildrakizumab-asmn) submitted by Sun Pharmaceutical Industries, Inc. The action updates …
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]
Phase 2 study evaluating the efficacy and safety of D-2570 in adults with moderate-to-severe plaque psoriasis; the trial has completed.
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of D-2570 in adults with moderate to severe plaque psoriasis is currently recrui…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
Clinical trial update for Deucravacitinib in adults with moderate-to-severe plaque psoriasis in Germany; the study is currently active but n…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-12-01FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for SELARSDI (USTEKINUMAB-AEKN), a biosimilar to ustekinumab.
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
A completed two-year real-world study assessing retention, quality of life, effectiveness and treatment patterns of secukinumab in adults wi…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? [Phase 2]
Phase 2 trial in plaque psoriasis evaluating early intervention with bimekizumab; currently recruiting at CHU Nice.
-
FDA approval · 2025-11-20FDA Approved: IMULDOSA — Supplemental Application (Accord BioPharma Inc.)
FDA approved a supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord BioPharma Inc. The action updates the regulatory status …
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period [Phase 3]
A Phase 3 study evaluates the efficacy and safety of TAK-279 for moderate-to-severe plaque psoriasis over 60 weeks, including withdrawal and…
-
FDA approval · 2025-11-19FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aeKn) from Teva Pharmaceuticals USA, Inc. The product is a ustekinumab bio…
-
FDA approval · 2025-11-18FDA Approved: USTEKINUMAB-TTWE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis [NA]
An ongoing trial to evaluate the effectiveness and safety of a TYK2 inhibitor in adults with moderate to severe plaque psoriasis is currentl…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 multiple-dose escalation study of ASKP1240 in adults with moderate-to-severe plaque psoriasis; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
This update reports the completion of an observational study of patients with moderate to severe chronic plaque psoriasis, sponsored by AbbV…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis [Phase 1]
This clinical trial update indicates that UA026 tablets are being studied in healthy adults and adults with moderate to severe plaque psoria…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis [Phase 3]
This update reports on a Phase 3 clinical trial of apremilast in children with mild to moderate plaque psoriasis. The study is currently act…
-
FDA approval · 2025-11-03FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for Ustekinumab (Stelara) from Janssen Biotech, Inc., related to regulatory changes to its label…
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment [Phase 3]
Phase 3 trial results evaluate the efficacy and safety of TAK-279 in adults with moderate-to-severe plaque psoriasis over 52 weeks.
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]
A Phase 2 study evaluating LY3972406 in adults with moderate-to-severe plaque psoriasis has completed, and results have been posted.
-
FDA approval · 2025-10-04FDA Approved: ZORYVE — Supplemental Application (Arcutis Biotherapeutics, Inc.)
The FDA approved a supplemental application for ZORYVE (roflumilast) from Arcutis Biotherapeutics, resulting in updated labeling for the pro…